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Background: Paediatric systemic lupus erythematosus (pSLE) exhibits an aggressive clinical phenotype with severe
complications and overall poor prognosis. The aim of this study was to analyse differential expression of low
molecular weight (LMW) serum protein molecules of pSLE patients with active disease in comparison to sera of
healthy age matched controls. Further, some of the differential expressed spots were characterised and identified
by Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) and liquid
chromatography (LC-MS).
Methods: 2D-PAGE was performed using pooled sera of active pSLE and age matched healthy controls. Gels were
silver-stained and differentially expressed protein spots were detected by automated image master platinum 2D
software. 79 ± 17 protein spots were detected for control gels and 78 ± 17 protein spots for patient gels. Of these
eleven protein spots were selected randomly and characterized by MALDI-TOF MS (five protein spots) and LC MS
(six protein spots) techniques.
Results: Out of the 11 protein spots, 5 protein spots were significantly upregulated viz., leiomodin 2 (LMOD2);
epidermal cytokeratin 2; immunoglobulin kappa light chain variable region; keratin 1 and transthyretin (TTR). Three
protein spots were significantly down regulated e.g., apolipoprotein A1 (APOA1); chain B human complement
component C3c; campath antibody antigen complex. Two protein spots (complement component C3; retinol
binding protein (RBP) were found to be expressed only in disease and one protein spot cyclohydrolase 2 was only
expressed in controls.
Conclusions: We conclude that 2-D maps of patients with active pSLE and controls differ significantly. In this pilot
study, using proteomic approach we have identified differential expressed proteins (of LMW) e.g., RBP, LMOD 2, TTR,
Component C3c Chain B and APO A1. However, in future, further studies need to confirm the physiological and
pathological role of these proteins in similar cohorts of pSLE.
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Table 1 Demographics and clinical parameters of







Median 12 13 0.213
Range 5-16 10-15








Cutaneous 25 (62.5) NA
Skin Biopsy 13 (32.5) NA
Renal 24 (60) NA
Renal Biopsy 10 (25) NA
Haematological 18 (45) NA
Oral ulcers 12 (30) NA
Musculoskeletal 12 (30) NA







III. Immunosuppressive therapy 3 10 (25)
Abbreviations: SLEDAI SLE disease activity index; Lupus nephritis class based
on international society of nephrology/renal pathology society classification
criteria (ISN/RPS), NA not applicable, 1 Values are represented as either median
& range or Number (percentage): N (%); 2p≤ 0.05 as significant;
3(methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and
cyclophosphamide).
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Systemic lupus erythematosus (SLE) is chronic auto-
immune disease with unknown aetiology and complex
pathogenesis. pSLE is more severe and exhibits a more ag-
gressive clinical course than adults. Genuine difficulties
are faced in diagnosing, classifying, and treating pSLE.
A proteomic approach is necessary to find proteins
expressed in the disease states, which may serve as diag-
nostic or prognostic marker, or serve as targets for thera-
peutics. Such an approach has yielded newer diagnostic
proteins in the other autoimmune diseases viz., myelin
protein Po in autoimmune inner ear disease [1], hetero-
geneous nuclear ribonucleoprotein A2/B1 in auto-
immune hepatitis, ?-enolase in Behcet’s disease [2],
?-enolase and its citrullinated molecule in rheumatoid
arthritis [3-7]. Traditional methods, such as ELISA or
western blotting, can only study several known proteins
simultaneously. On the contrary, 2-dimensional poly
acryl amide gel electrophoresis (2D-PAGE) combined
with protein identification by mass spectrometry (MS)
which can help to identify a very large number of un-
known proteins [8,9]. Proteomic approaches in auto-
immune diseases are also required in addition to gene
expression studies as the latter has many limitations.
First, diseases manifest not at the level of RNA transcrip-
tion, but rather at the level of the protein. Second, there
is a frequently non predictive correlation between RNA
expression and protein expression and function [10,11].
Messenger RNA undergoes a variety of processing events
that can profoundly affect cell phenotype yet are not
revealed in current transcriptional profiles [12-14]. Third,
protein function can be regulated by posttranslational
modifications by enzymes such as kinases or proteases.
In the present study, we attempted a proteomic ap-
proach and performed comparative protein analysis of sera
of pSLE and healthy control subjects by 2D-PAGE fol-
lowed by Matrix Assisted Laser Desorption Ionization and
time of flight (MALDI-TOF) and Liquid chromatography-
mass spectrometry (LC-MS) for the identification and
characterization of limited number of some significantly
expressed proteins spots. The function and classification
of these proteins were then determined by searching the
public database.
Methods
Forty consecutive pSLE patients (5–16 years of age) were
recruited from the Division of Allergy Immunology,
Advanced Paediatrics Centre, Post Graduate Institute of
Medical Education and Research (PGIMER), Chandi-
garh, India. The diagnosis of pSLE patients was based on
the American College of Rheumatology (ACR) criteria
for classification [15]. Twenty healthy and age-matched
volunteers served as controls. Study was carried out be-
tween March 2007 and April 2011. The mean age of thepSLE patients was 15.2 years (range 5–16). The median
SLE Disease Activity Index (SLEDAI) scores were 15
(range of period 4–26) [16]. All patients were positive at
a significant titer for antinuclear antibodies included in
the study. Patients with overlap syndrome were excluded
from the study. All patients were on treatment using
standard protocols incorporating, glucocorticoids and
immunosuppressive agents (e.g. cyclophosphamide and
azathioprine). Patient information in regard to demo-
graphic data, cumulative clinical features, serological
profile, and medications were retrieved from medical
records (shown in Table 1). The study protocol was
approved by the Institute Ethics Committee. All parents/
guardians of pSLE patients gave a written informed
consent.
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Sera were separated from whole blood of pSLE and
healthy volunteer children. Blood samples were collected
(in autoclaved glass tubes) and left for 1 h at 37°C to
allow it to clot. Further, samples were left at 4°C over-
night to allow the clot to contract. Using a glass pasteur
pipette, the clot was loosened carefully from the side of
the tube. A care has been taken to not to lyse the red
cells as they cannot then be separated from the serum.
Serum was centrifuged at 4000 rpm for 20 min at 4°C.
Serum was removed from the clot by gently pipetting off
into a clean tube. It was stored at −20°C.
Comparative protein analysis of sera of pSLE and healthy
control subjects by 2-Dimensional Poly acryl amide gel
electrophoresis (2D-PAGE)
Protein concentration from sera was estimated by
BIORAD protein assay (modified Bradford assay). Mean
concentration of protein in sera from control sample was
estimated as 66.9 mg/ml and from SLE disease sample as
65 mg/ml. Proteins (100 μg) were cleaned up using 2-D
Clean-Up Kit (GE Healthcare) also as described by the
manufacturer. The dried protein pellet was then redis-
solved in 250 μl swelling solution containing 7 M urea,
2 M thiourea, 2% CHAPS, 20 mM DTT and 0.5% IGP
buffer pH 3–10. 2-D electrophoresis Immobilized pH
gradients (IPG) isoelectric focusing (IEF) of the protein
(100 μg) was performed according to the guideline of
IPG phor IEF system (GE Healthcare, Piscataway, NJ,
USA). Thirteen centimetre immobilized pH 4–7 gradient
IPG strips (GE Healthcare, Piscataway, NJ, USA) were
chosen, and IEF were run at 20°C using the following
conditions: 12 h rehydration, 1 h at 500 V, 1 h at 1000 V
and at 8000 V to a total voltage × time of 60 KVh. Strips
were then equilibrated by incubating in 6 M urea, 30%
glycerol, 2% sodium dodecyl sulfate (SDS), 50 mM
Tris/Cl pH 8.8 (SDS equilibration buffer solution) con-
taining 1% DTT, 10 ml per strip for 15 min at room
temperature, followed by an incubation for 15 min at
room temperature in 10 ml per strip SDS equilibration
buffer solution containing 2.5% iodoacetamide and a
trace of bromophenol blue. Strips were then placed on
top of 12.5% SDS polyacrylamide gel electrophoresis gels
and electrophoresed at 30 milli ampere per gel until the
bromophenol blue dye front had reached the bottom of
the gel. Each sample was run on duplicate gels.
Silver staining and image analysis
Gels were silver stained using the improved protocol com-
patible with mass spectrum analysis [17]. After gel scan-
ning, images were analyzed using Image Master 2D
Platinum 5.0 software (GE Healthcare, Piscataway, NJ,
USA). For each gel, the preliminary analysis included pro-
tein spot detection, editing, filtration and quantification.Spots were quantitated as a fraction of the total volume of
protein spots on the gel. One typical control gel with the
most protein spots was then set as reference gel, to which
all the other gels were matched. Match rates of each group
of gels were calculated automatically by the software.
Class report analysis was run on the software and each
spot group with a between-class ratio of more than two or
less than 0.5 was statistically analyzed using the Mann–
Whitney rank sum test, two-tailed.
MALDI-TOF-TOF-MS and database searching
The differentially expressed protein spots were excised
and collected followed by washing in ex-ion water and
destaining through acid ammonium carbonate of
50 mmol/L plus 50% acetonitrile. Samples were then
treated with trypsin overnight at 37°C. The peptide seg-
ments were drawn through 0.1% trifluoroacetic acid
(TFA) plus 50% acetonitrile and dried by nitrogen gas.
The loading samples were covered by matrix solution
(0.1% TFA and 50% acetonitrile) of 0.8 L. After air-dry-
ing, the samples were analyzed by peptide mapping fin-
gerprint (PMF) and MALDI-TOF-TOF-MS, which was
rectified by the inner markers including the base peak
and the inscribed trypsin peak. The obtained peptide
mass fingerprints were used to search through the
SWISS-PROT and NCBInr database by the Mascot
search engine, with which MS/MS ion search was also
finished. In addition, the amino acid sequences of the
peptides were deduced with the peptide sequencing pro-
gram MasSeq.
Results
2-D electrophoresis maps of sera in control and patients
with pSLE
Using gel image analysis software Image Master 2D Plat-
inum 5.0, we compared 2D maps of sera between
patients with SLE and healthy controls. The images were
found to be similar either between gels or between
groups. There were approximately more than 500 spots
that could be visualized manually in the 2D gel images
of both pSLE patients and controls. After comparing
with the reference gel, match rates of 63%± 4% and
62%± 4% were for control and patient gels, respectively.
Simultaneously, 79 ± 17 spots were detected for control
gels and 78 ± 17 for patient gels. Figure 1 shows a typical
control gel and a typical patient gel, respectively.
Differentially expressed proteins between patients with
SLE and controls
To identify proteins that were differentially expressed in
one group with respect to the other, we compared the
value of expression of each spot in the patient group as
a ratio of the value of expression of that spot in the con-
trol group using the ‘class report’ command of Image
Figure 1 Two dmensional PAGE gel picture of SLE control and patient usinf serum, showing differentially espressed spots and selected
differential spots were further MALDI and LC-MS analysis (IEF at pH 3-10, IPG strip-17cm). The molecular weight of the protein markers
are indicated on the sides of each gel.
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resulted in 79 spot groups with a between-class ratio of
more than one or less than 0.5. The average value for
these spots on the two duplicate gels per individual was
calculated, and these average values were then compared
using the Mann–Whitney rank sum test, two-tailed. Out
of 79 spots, we selected 11 spots for the identification
and characterization by MALDI-TOF and LCMS ana-
lysis. These protein spots were chosen randomly from
the low molecular weight region, preferably at a molecu-
lar mass lower than 20 KD, as can be seen from their lo-
cation and labeling in the patent and control gels (Please
see Figure 1). LMW proteome, low abundant proteins
are especially important for biomarker discovery in SLE.
Because this region contains biologic mediators (cyto-
kines, chemokines, growth factors) that are expected to
be involved in disease pathogenesis. Some of these med-
iators have been found in active SLE renal tissue and
may reflect organ-specific tissue injury [18]. 2D PAGE
followed by MS has been shown earlier to detect urine
proteins that discriminate between ISN/RPS lupus neph-
ritis classes [19]. In our cohort, all these 11 spots had p
value of less than 0.05. There were spots which were
showing low score in MALDI-TOF. For them we have
to proceed further for LC-MS/MS analysis. Six protein
spots were up-regulated (labelled as A −11, A-16, A-17,
A-18, A-21), and five protein spots were down-regulated
(labelled as A-10, A-13 and W) in patients with pSLE
(Figure 2). D19 and D31 were the spots highly expressed
in the patients. The median volume of the eleven spots
in the two groups was also calculated. Figures 3A and
3B are enlarged areas of the control and patient gelsshowing a comparison of the expressions of spot A10
and A21 in these gels respectively.
Identification and characterization of proteins by Mass
Spectrometry (MALDI-TOF- MS and LCMS)
Differentially expressed protein spots were excised from
the gels, digested with trypsin and the proteolytic frag-
ments analyzed by MALDI-TOF mass spectrometry as
described in materials and methods section. We identi-
fied eleven proteins, which are summarized in Table 2 &
3. Differentially expressed protein spots, their fold regu-
lation values, spot categorization (U, up-regulated in
pSLE; D, down-regulated in pSLE), molecular weight
(MW) in daltons (Da), isoelectric point (pI), sequence
coverage (%) of matching peptides and their spectrum
analysis are shown in Tables 1 and 2 and Figure 4.
Discussion
Recently, the proteomic approach has been successively
used to identify the biomarkers in skin, kidney or plasma
of SLE patients [5,6,20,21]. However, to the best of our
knowledge, no such study has been reported on pSLE
patients using sera from north India. In this preliminary
study, we attempted a proteomic approach such as 2-DE
and MALDI-TOF MS and LC-MS to find candidate
molecules in sera of pSLE patients with active disease in
comparison to age matched healthy controls.
On evaluation of our data five differentially expressed
protein spots (within low molecular weight region) were
identified: Retinol-binding protein, Leiomodin2, Trans-
thyretin, Component C3c Chain B and Apolipoprotein A1
(Table 2).
Figure 2 Two dimensional poly acryl amide gel pictures of control and disease using sera shows spots categorization-Spots 1-11:
spots present only in control, spots 12-31: Spots present only in diseased, spots A-Z, A1-A22: Spots present in both control and
diseased but are differentially expressed.
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binds to retinol, was found to be over expressed in sera
of pSLE patients but not in controls. Its role has been
previously described to be associated with nephritis es-
pecially in children [22,23]. It has also been described as
a urinary marker of proximal renal tubular dysfunction
[24-26]. We have described the increased expression of
RBP protein spots in pooled sera of pSLE patients withFigure 3 A Enlarged areas of the control and patient gels showing a
(down regulated in disease as indicated by black arrow) in these gels
B Enlarged areas of the control and patient gels showing a comparison of
expressed in disease gel (indicated by black arrow) in these gels. On the leactive disease and compared them with controls. It
would be important to quantitate this protein and dis-
criminate between different sub-groups of patients with
pSLE, for example active and non-active disease and
with other clinical manifestations (e.g. Lupus nephritis
class based on international society of nephrology/renal
pathology society classification criteria (WHO/ISN/RPS)
which was not covered in this study.comparison of the expressions of spot A10 Apolipoprotein A1
. On the left is a control gel and on the right is a patient gel.
the expressions of spot A21 Transthyretin Variant del 122 was over
ft is a control gel and on the right is a patient gel.
Table 2 Spectrum analysis (MALDI-TOF & LC-MS) results 11 spots
S. No Spot ID Accession no
(Database =
NCBI nr)













1. A-10 (LC-MS) gi|178775 Pro-apo-lipoprotein
[Homo sapiens]
28944 5.13 7% 213
2. A-11 (MALDI-TOF) gi|51095091 Leiomodin 2(Cardiac)
[Homo sapiens]
59366 9.9 14.5% 43.7%
(25167 cnts)
69.4 16




21596 5.8 18.1% 36.3%
(13319 cnts)
68.0 17
4. A-16 (LC-MS) gi|269849769 Epidermal cytokeratin
2 [Homo sapiens]
59020 5.13 7% - 171 -
5. A-17 (LC-MS) gi|29836906 Immunoglobulin kappa
light chain variable
region [Homo sapiens]
8811 8.65 20% - 62 -
6. A-18 (LC-MS) gi|7331218 Keratin 1[Homo sapiens] 66149 8.16 3% - 63 -
7. A-21 (MALDI-TOF) gi|212374952 Chain A, Crystal structure
of Transthyretin Variant
del 122[Homo sapiens]
13798 5.35 48.8% 33.4%
(18627 cnts)
85.4 15
8. W (LC-MS) gi|5542161 Chain H, 1.9a Structure
Of The Therapeutic
Antibody Campath-1 h
Fab In Complex With A
Synthetic Peptide
Antigen[Homo sapiens]
23740 9.03 6% - 105





37463 10.0 21.3% 37.3%
(18238 cnts)
67.00 14
10 D19 (MALDI-TOF) gi|119589476 Complement component
C3, partial [Homo sapiens]
144417 7.8 7.5% 51.0%
(34497 cnts)
67.2 21
11. D31 (LC-MS) gi|18088326 Retinol binding protein
[Homo sapiens]
23371 5.77 10% - 112 -
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Lmod 2, was overexpressed in sera of pSLE patients. It is
a 547 amino acid protein that is specifically expressed in
heart and skeletal muscles. Leiomodin 2 is encoded by aTable 3 Summary of differentially expressed protein spots sh
calculated by PD Quest Software)











11 Disease-31 0gene that is located near the hypertrophic cardiomyop-
athy locus CMH6 on chromosome 7, suggesting that
Lmod2 may be involved in that disease process. Tsukada
et al. have identified a function of Lmod2 in theowing Fold-regulation (Ratio: Diseased/Control as












Figure 4 MALDI MS analysis report for a representative protein spot.
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Lmod 2 results in loss of Tmod1 assembly and elong-
ation of the thin filaments from their pointed ends. Pri-
mary function of Lmod2 is to maintain thin filament
lengths in the mature heart. It has been shown to be es-
sential for efficient contractile activity of heart and
striated muscles. Presence of increased protein in dis-
eased sera may correlate with myocarditis and polymyo-
sitis in pSLE patients. This assumption also requires
further investigation [27-29].
Transthyretin (TTR) is a serum and cerebrospinal
fluid carrier of the thyroid hormone thyroxine (T4) and
retinol [30]. TTR variant Del 122 Val protein had a higherexpression in pSLE sera compared to healthy controls.
Plasma TTR originates primarily from the liver [31]. TTR is
known to be associated with the amyloid diseases, senile
systemic amyloidosis, familial amyloid polyneuropathy, and
familial amyloid cardiomyopathy [32-34]. The presence of
this protein in our study suggests that pSLE patients have
potential to develop secondary amyloidosis. Sequential
quantitation of this protein in long surviving SLE patients
and its relationship with development of amyloidosis
should be addressed in future studies.
Apolipoprotein A1 (APO A1) is a major constituent of
the high density lipoprotein (HDL) complex which acts in
cholesterol homeostasis and also has anti-inflammatory
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Serum apolipoprotein (apo) A-I is also considered to be
an immune regulator and can suppress pro-inflammatory
cytokines generated by activated T cell in some auto-
immune diseases [36]. The present study showed lower
expression of apolipoprotein A1 in lupus patients as
compared to healthy controls. Zhang, B., et al. (2010)
showed lower level of Apo-A-I are seen in SLE and
rheumatoid arthritis patients [37]. Further, it has been
shown that low levels of this protein are associated
with increased risk for cerebrovascular disease and
atherosclerosis [38]. This interesting finding in our
cohort re-iterates that in future therapeutic modula-
tion of this protein may prevent long term complica-
tions of SLE due to exaggerated atherosclerosis.Conclusions
In this preliminary proteomic study performed on pooled
sera of pSLE patients with active disease, we identified
some significant differentially expressed proteins relevant
to a pSLE cohort. All novel proteins need validation by
ELISA, western blot or by high throughput protein micro-
array technology. Furthermore, the role of these proteins
as prognostic markers in adult and pediatric SLE patients
needs further investigation.
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